FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI
In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics
Search Committee Finishes Job, Submits Choices To Califano
New ACS Grants to Fund ‘Critical, Urgent’ Research
Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes
UICC Announces Grant Programs to Continue
NCI Goofs On Contract Notice, Won’t Change Improper Deadline
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ









